GoodRx offers coupons for reduced prescription drug prices at retail pharmacies. The company says patients will be able to use GoodRx to self-pay for both Ozempic and Wegovy at the $499-per-month price at 70,000 U.S. retail pharmacies.

GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX shares into the strength before they crash again.

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a household name, famous for helping people manage their weight, but this new indication could be a significant development. Here's why.

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click here to find out why GDRX is a Buy.

GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new partnership with Novo Nordisk.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

Novo said cash-paying Americans can now buy Ozempic for $499 per month through various channels including its official website.